List view / Grid view

Schizophrenia

Filter the results

 

news

Positive Phase 1b results for Heptares’ HTL9936

10 February 2016 | By Victoria White

HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia...